NEOLISE Sculpt Review: Vitals on a Contested Body-Composition Program

NEOLISE Sculpt, a telehealth program marketed to adults interested in body composition and visceral fat reduction, is under scrutiny in a new review. This program, which uses a compounded preparation containing tesamorelin, is being evaluated for its potential as a next-step option for GLP-1 users, particularly those who have found their current treatments insufficient for their goals.

NEOLISE Sculpt is positioned by the brand for adults over 35 with declining growth hormone levels, individuals already on GLP-1 medications, and those who have struggled to move fat in their midsection despite consistent exercise and diet. The program offers three-, six-, and twelve-month terms, with upfront payments ranging from $597 to $2,028, equivalent to $169 to $199 per month. A 48-hour cancellation window is available before processing.

The NEOLISE platform, a brand of Omni Health Ventures Inc., does not make prescribing decisions or dispense medication. Instead, it works with an independent medical group to provide a telehealth evaluation. The program is marketed as a "missing piece" in a body-composition journey, but the clinical evidence supporting this claim is being closely examined.

The NEOLISE program is based on a 44-amino-acid analog of growth hormone-releasing hormone (GHRH), which is also the active ingredient in EGRIFTA WR, an FDA-approved drug for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. However, the FDA approval does not extend to the compounded version used in NEOLISE Sculpt. The clinical trials cited by NEOLISE, which involve adults with HIV-associated lipodystrophy, show a 9.9% average reduction in visceral fat and a 37% reduction in liver fat relative to placebo. These results are not directly applicable to the general population NEOLISE markets to.

NEOLISE's site also cites a 2012 controlled study published in JAMA Neurology, which reported mixed cognitive benefits in older adults. However, this trial does not establish a cognitive benefit for the general population NEOLISE markets to. The studies reviewed do not directly evaluate NEOLISE Sculpt, and the results from the HIV-associated lipodystrophy population cannot be assumed to apply to other groups.

The mechanism of action for tesamorelin is well-documented. It stimulates the pituitary gland to release growth hormone in a more natural, pulsed pattern, which subsequently increases IGF-1 production. NEOLISE characterizes this as targeting visceral fat. However, whether this mechanism translates to the specific outcomes NEOLISE claims for its target population remains unverified.

In summary, NEOLISE Sculpt is a potentially valuable option for individuals interested in body recomposition and visceral fat reduction. However, buyers should be aware that the clinical evidence supporting the program's claims is limited and does not directly apply to the general population. Prospective users should discuss the program with a qualified healthcare professional to determine if it is appropriate for their specific needs.